On March 28, Ge Longhui | Kangchen Pharmaceutical (01681.HK) announced that in 2023, the Group achieved sales revenue of about RMB 2.59 billion, an increase of about 10.7% over the previous year; profit attributable to the company's equity shareholders was approximately RMB 780 million, an increase of about 14.9% over the previous year. Basic and diluted earnings per share were approximately RMB 0.99 and RMB 0.98 respectively. The Board proposed a final dividend of HK$0.3 per share for the year 2023.
Looking at the business segment, Kangchen Pharmaceutical's sales revenue in 2023 was about RMB 2.2 billion, an increase of about 10.8% over the previous year. Among them, the sales revenue of nephrology drugs was approximately RMB 1.74 billion in 2023, an increase of about 11.0% over the previous year. The Group's leading product, uretoxin granules, continued to grow steadily, achieving sales revenue of about RMB 1.65 billion, an increase of about 10.2% over the previous year, and stabilized in the leading position in modern pharmaceuticals for oral nephropathy. The Yulin Pharmaceutical Division's sales revenue in 2023 was approximately RMB 40 billion, an increase of about 10.2% over the previous year, and profit of about RMB 40 million. It has achieved restorative profits for three consecutive years.